Non-Melanoma Skin Cancers

The FDA has accepted Biofrontera’s supplemental new drug application seeking approval of Ameluz photodynamic therapy for superficial basal cell carcinoma (sBCC), with a decision expected by September 28, 2026.

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.

Alpha Tau Medical advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC), offering a novel, localized treatment option with minimal toxicity.

New research confirms how skin tension line-oriented grafting enhances cosmetic outcomes in basal cell carcinoma surgery, improving aesthetics without compromising quality of life.

Topline results are expected in the first quarter of 2026.

Researchers are developing an innovative mRNA vaccine targeting Merkel cell carcinoma, enhancing T cell immunity and offering new hope for effective treatment.

Findings suggest immune dysregulation and chronic inflammation in atopic dermatitis may contribute to increased skin cancer susceptibility.

Vishal A. Patel, MD, discusses cemiplimab's FDA approval as a groundbreaking adjuvant therapy for high-risk cutaneous squamous cell carcinoma patients.

Discover expert insights on cutaneous oncology from George Martin, MD, focusing on innovative treatments for skin cancers at Maui Derm NP+PA Fall.

Medicus Pharma has initiated a phase 2 trial in the UAE for a non-invasive BCC treatment, aiming to revolutionize skin cancer care.

Merck's pembrolizumab gains Health Canada approval for innovative perioperative treatment of advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Immutep advances eftilagimod alfa for head and neck squamous cell carcinoma, targeting patients with low PD-L1 expression and limited treatment options.

Ata Moshiri, MD, MPH, FAAD, spoke about pathology interpretation and patient communication at Elevate-Derm Summer 2025, enhancing skin cancer diagnosis.

Discover how gene expression profiling transforms melanoma and SCC management, enhancing personalized treatment strategies and improving patient outcomes in skin cancer care.

At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.

At a recent Dermatology Times Case-Based Roundtable event, Andrew Baker, PA-C, MBA, explored the management of skin cancers with GEP testing through 4 complex cases.

Renata Block, DMSc, MMS, PA-C, interviews Andrew Baker, PA-C, MBA, to discuss his role as a sub-investigator in Castle Biosciences’ UTILISE study for cSCC.

At this year's Fall Clinical PA/NP meeting, Darrell Rigel, MD, MS, spoke about the evolving role of GEP in managing melanoma and squamous cell carcinoma.

Explore the latest insights, strategies, and treatments for patients with skin cancer as Dermatology Times looks back on Melanoma and Skin Cancer Awareness Month.

The Skin Cancer Foundation's gala raises over $800,000, featuring Christie Brinkley and highlighting vital skin cancer awareness initiatives and personal stories.

The Photobiology Committee also issues a public safety warning regarding sun protection misinformation amid growing rates of skin cancer in the U.S.

Additionally, BCC surgery candidates have been older with more comorbidities since the pandemic began.

High response rates and no systemic toxicity in multiple nonmelanoma skin tumors were observed in this vulnerable patient population.

John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.